MX2017013496A - Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk). - Google Patents

Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk).

Info

Publication number
MX2017013496A
MX2017013496A MX2017013496A MX2017013496A MX2017013496A MX 2017013496 A MX2017013496 A MX 2017013496A MX 2017013496 A MX2017013496 A MX 2017013496A MX 2017013496 A MX2017013496 A MX 2017013496A MX 2017013496 A MX2017013496 A MX 2017013496A
Authority
MX
Mexico
Prior art keywords
host disease
versus host
graft versus
treatment
chronic graft
Prior art date
Application number
MX2017013496A
Other languages
English (en)
Inventor
Haw- Ling Lin Joseph
A Di Paolo Julie
Lee Lin Shao-
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2017013496A publication Critical patent/MX2017013496A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción provee métodos para utilizar compuestos inhibidores de Syk en el tratamiento de enfermedad de injerto contra hospedero (GVHD) en un humano, incluyendo enfermedad aguda de injerto contra hospedero (aGVHD) y enfermedad crónica de injerto contra hospedero (cGVHD), incluyendo el uso de compuestos que se seleccionan a partir del grupo que consiste de las siguientes fórmulas: (I) y (II).
MX2017013496A 2015-04-21 2016-04-19 Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk). MX2017013496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562150691P 2015-04-21 2015-04-21
PCT/US2016/028303 WO2016172117A1 (en) 2015-04-21 2016-04-19 Treatment of chronic graft versus host disease with syk inhibitors

Publications (1)

Publication Number Publication Date
MX2017013496A true MX2017013496A (es) 2018-02-09

Family

ID=55854820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013496A MX2017013496A (es) 2015-04-21 2016-04-19 Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk).

Country Status (14)

Country Link
US (1) US20160375019A1 (es)
EP (1) EP3285808A1 (es)
JP (1) JP2018513173A (es)
KR (1) KR20170137200A (es)
CN (1) CN107530354A (es)
AU (1) AU2016252387A1 (es)
BR (1) BR112017022323A2 (es)
CA (1) CA2983611A1 (es)
EA (1) EA201791946A1 (es)
HK (2) HK1244453A1 (es)
MX (1) MX2017013496A (es)
SG (1) SG11201708075RA (es)
TW (1) TW201711685A (es)
WO (1) WO2016172117A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2745871C (en) 2008-12-08 2018-02-20 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
US9562056B2 (en) 2010-03-11 2017-02-07 Gilead Connecticut, Inc. Imidazopyridines Syk inhibitors
US9657023B2 (en) 2013-07-30 2017-05-23 Gilead Connecticut, Inc. Polymorph of Syk inhibitors
WO2015017610A1 (en) 2013-07-31 2015-02-05 Gilead Sciences, Inc. Syk inhibitors
EA201690608A1 (ru) 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. Способы лечения раковых заболеваний
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
NZ726365A (en) 2014-07-14 2018-06-29 Gilead Sciences Inc Combinations for treating cancers
WO2017106564A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
EP3512519A1 (en) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Syk inhibitors
US20190382483A1 (en) * 2017-02-17 2019-12-19 Ose Immunotherapeutics NEW USES OF ANTI-SIRPg ANTIBODIES
KR102399996B1 (ko) 2017-08-25 2022-05-20 길리애드 사이언시즈, 인코포레이티드 Syk 억제제의 다형체
US11746110B2 (en) 2018-07-17 2023-09-05 Shenzhen Targetrx, Inc. Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity
WO2020172431A1 (en) 2019-02-22 2020-08-27 Gilead Sciences, Inc. Solid forms of condensed pyrazines as syk inhibitors
CN112939983A (zh) * 2021-02-01 2021-06-11 暨明医药科技（苏州）有限公司 一种SYK激酶抑制剂Lanraplenib的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
US8450321B2 (en) * 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
KR20170013414A (ko) 2008-12-08 2017-02-06 질레드 코네티컷 인코포레이티드 이미다조피라진 ｓｙｋ 억제제
MD4684B1 (ro) 2013-07-30 2020-03-31 Gilead Connecticut INc. Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
US9657023B2 (en) 2013-07-30 2017-05-23 Gilead Connecticut, Inc. Polymorph of Syk inhibitors
EA201690608A1 (ru) * 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. Способы лечения раковых заболеваний
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI662037B (zh) * 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑

Also Published As

Publication number Publication date
CA2983611A1 (en) 2016-10-27
KR20170137200A (ko) 2017-12-12
AU2016252387A1 (en) 2017-10-19
US20160375019A1 (en) 2016-12-29
HK1249054A1 (zh) 2018-10-26
TW201711685A (zh) 2017-04-01
CN107530354A (zh) 2018-01-02
WO2016172117A1 (en) 2016-10-27
JP2018513173A (ja) 2018-05-24
BR112017022323A2 (pt) 2018-07-03
HK1244453A1 (zh) 2018-08-10
EP3285808A1 (en) 2018-02-28
SG11201708075RA (en) 2017-11-29
EA201791946A1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
MX2017013496A (es) Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk).
ZA202208792B (en) Methods of treating and preventing graft versus host disease
PH12018502234A1 (en) Treatment of cancer with tor kinase inhibitors
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX2017001656A (es) Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
EA201791133A1 (ru) Ингибиторы erk
MX2021006734A (es) Metodo para tratar el cancer.
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
MX2018001737A (es) Mecanismo de resistencia a inhibidores de bromodominio bet.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
WO2015143424A3 (en) Methods of treating cancer
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
IL251881A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.